DSGN

Design Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Design Therapeutics sales and earnings growth
DSGN Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -40.00%
  • FCF Y/Y↓ -12.93%
Design Therapeutics gross and profit margin trends
DSGN Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -32.80%
Design Therapeutics net debt vs free cash flow
DSGN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Design Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗